New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses ...

SLXN

<p>新的積極的臨牀前數據表明，在臨牀相關劑量下，藥物成功分佈到肝臟、腹膜和肺部，並且腫瘤負擔顯著減少</p>

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Silexion Therapeutics 報告了積極的臨牀前數據，表明在系統給藥後，SIL204 能夠到達並在主要胰腺癌轉移部位發揮作用